• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Combining novel agents in chronic lymphocytic leukemia: Greater than the sum of its parts?

作者信息

de Weerdt Iris, Kater Arnon P

机构信息

Department of Hematology, Cancer Center Amsterdam, Amsterdam Infection and Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Lymphoma and Myeloma Center Amsterdam, LYMMCARE, Amsterdam, The Netherlands.

出版信息

Hemasphere. 2019 Jun 30;3(Suppl). doi: 10.1097/HS9.0000000000000197. eCollection 2019 Jun.

DOI:10.1097/HS9.0000000000000197
PMID:35309786
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8925669/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caf4/8925669/91b5a2ba7ff7/hs9-3-0044-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caf4/8925669/91b5a2ba7ff7/hs9-3-0044-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caf4/8925669/91b5a2ba7ff7/hs9-3-0044-g001.jpg

相似文献

1
Combining novel agents in chronic lymphocytic leukemia: Greater than the sum of its parts?慢性淋巴细胞白血病中新型药物的联合应用：是否大于各部分之和？
Hemasphere. 2019 Jun 30;3(Suppl). doi: 10.1097/HS9.0000000000000197. eCollection 2019 Jun.
2
Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia.扩大慢性淋巴细胞白血病的治疗手段：慢性淋巴细胞白血病治疗中新型药物的综述
J Oncol Pharm Pract. 2017 Oct;23(7):502-517. doi: 10.1177/1078155216656929. Epub 2016 Jun 29.
3
AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments.AMD3100 破坏慢性淋巴细胞白血病细胞与间充质基质或类滋养细胞为基础的微环境之间的串扰：与慢性淋巴细胞白血病治疗相关的临床前证据。
Haematologica. 2012 Apr;97(4):608-15. doi: 10.3324/haematol.2011.052779. Epub 2011 Nov 4.
4
Purine metabolism enzymes and immunological phenotype in chronic B-cell malignancies: chronic lymphocytic leukemia, prolymphocytic leukemia and hairy cell leukemia.慢性B细胞恶性肿瘤中的嘌呤代谢酶与免疫表型：慢性淋巴细胞白血病、幼淋巴细胞白血病和毛细胞白血病
Neoplasma. 1990;37(6):693-701.
5
Changing landscape of frontline therapy in chronic lymphocytic leukemia.慢性淋巴细胞白血病一线治疗的格局变化。
Leuk Lymphoma. 2020 Mar;61(3):525-535. doi: 10.1080/10428194.2019.1688321. Epub 2019 Nov 15.
6
[Therapeutic Options for "Slow go" Patients with Chronic Lymphocytic Leukemia].[慢性淋巴细胞白血病“进展缓慢”患者的治疗选择]
Klin Onkol. 2015;28 Suppl 3:3S30-8. doi: 10.14735/amko20153s30.
7
Enhancement of fludarabine sensitivity by all-trans-retinoic acid in chronic lymphocytic leukemia cells.全反式维甲酸增强慢性淋巴细胞白血病细胞对氟达拉滨的敏感性。
Haematologica. 2012 Jun;97(6):943-51. doi: 10.3324/haematol.2011.051557. Epub 2011 Dec 16.
8
[Small Molecules in the Treatment of Chronic Lymphocytic Leukemia in 2015 and in the Near Future].[2015年及不久的将来用于治疗慢性淋巴细胞白血病的小分子药物]
Klin Onkol. 2015;28 Suppl 3:3S45-9. doi: 10.14735/amko20153s45.
9
Expression of encoding novel ROR1 binding partner is robust predictor of survival in chronic lymphocytic leukemia.编码 novel ROR1 结合伴侣的表达是慢性淋巴细胞白血病生存的有力预测指标。
Haematologica. 2018 Feb;103(2):313-324. doi: 10.3324/haematol.2017.178699. Epub 2017 Nov 9.
10
Infections in patients with chronic lymphocytic leukemia treated with fludarabine.接受氟达拉滨治疗的慢性淋巴细胞白血病患者的感染情况
Ann Intern Med. 1998 Oct 1;129(7):559-66. doi: 10.7326/0003-4819-129-7-199810010-00010.

本文引用的文献

1
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.伊布替尼、氟达拉滨、环磷酰胺和奥滨尤珠单抗（iFCG）方案治疗伴有IGHV 突变且无 TP53 异常的慢性淋巴细胞白血病（CLL）。
Leukemia. 2021 Dec;35(12):3421-3429. doi: 10.1038/s41375-021-01280-8. Epub 2021 May 18.
2
CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia.CLL2-BIG：苯达莫司汀、伊布替尼和奥滨尤妥珠单抗（GA101）序贯治疗慢性淋巴细胞白血病。
Leukemia. 2019 May;33(5):1161-1172. doi: 10.1038/s41375-018-0313-8. Epub 2018 Dec 19.
3
Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL.
奥滨尤妥珠单抗预处理可降低肿瘤溶解风险，同时保持慢性淋巴细胞白血病患者 Venetoclax + 奥滨尤妥珠单抗治疗后 MRD 阴性。
Blood Adv. 2018 Dec 26;2(24):3566-3571. doi: 10.1182/bloodadvances.2018019422.
4
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.维奈托克联合利妥昔单抗治疗复发/难治性慢性淋巴细胞白血病的持续时间：MURANO Ⅲ期研究的治疗后随访结果，可消除微小残留病灶并延长生存。
J Clin Oncol. 2019 Feb 1;37(4):269-277. doi: 10.1200/JCO.18.01580. Epub 2018 Dec 3.
5
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.伊布替尼联合奥滨尤妥珠单抗与苯丁酸氮芥联合奥滨尤妥珠单抗一线治疗慢性淋巴细胞白血病（ILLUMINATE）：一项多中心、随机、开放标签、III 期临床试验。
Lancet Oncol. 2019 Jan;20(1):43-56. doi: 10.1016/S1470-2045(18)30788-5. Epub 2018 Dec 3.
6
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.复发性 Gly101Val 突变的获得使慢性淋巴细胞白血病患者对 Venetoclax 产生耐药性。
Cancer Discov. 2019 Mar;9(3):342-353. doi: 10.1158/2159-8290.CD-18-1119. Epub 2018 Dec 4.
7
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.伊布替尼方案与化疗免疫治疗在未经治疗的老年 CLL 患者中的比较。
N Engl J Med. 2018 Dec 27;379(26):2517-2528. doi: 10.1056/NEJMoa1812836. Epub 2018 Dec 1.
8
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.苯达莫司汀后继奥滨尤妥珠单抗和维奈克拉治疗慢性淋巴细胞白血病（CLL2-BAG）：多中心、开放标签、2 期试验的主要终点分析。
Lancet Oncol. 2018 Sep;19(9):1215-1228. doi: 10.1016/S1470-2045(18)30414-5. Epub 2018 Aug 13.
9
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.奥滨尤妥珠单抗、伊布替尼和维奈托克治疗复发/难治性慢性淋巴细胞白血病的 1b 期研究。
Blood. 2018 Oct 11;132(15):1568-1572. doi: 10.1182/blood-2018-05-853564. Epub 2018 Aug 15.
10
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.伊布替尼联合利妥昔单抗治疗华氏巨球蛋白血症的 3 期临床试验。
N Engl J Med. 2018 Jun 21;378(25):2399-2410. doi: 10.1056/NEJMoa1802917. Epub 2018 Jun 1.